Abionyx PharmaFRA:609 +1.17%15 Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus rates FRA:609 with a GF Score™ of 15/100 and a GF Value™ of €0.80 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 151 Biotechnology companies, Abionyx Pharma ranks worse than 662250.99% on this metric.
As of today (2026-06-25), the Trailing Annual Dividend Yield of Abionyx Pharma is 0.00%.
The historical rank and industry rank for Abionyx Pharma's Dividend Yield % or its related term are showing as below:
FRA:609's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.5 * Ranked among companies with meaningful Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for Abionyx Pharma's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:609 vs VRTX, REGN, ALNY: Dividend Yield % Comparison
For the Biotechnology subindustry, Abionyx Pharma's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abionyx Pharma Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abionyx Pharma's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Abionyx Pharma's Dividend Yield % falls into.
Abionyx Pharma (FRA:609) has a Dividend Yield % of 0.00% as of Jun. 25, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Abionyx Pharma and its competitors. According to the industry distribution chart, Abionyx Pharma ranks #999999 out of 151 companies in the Biotechnology industry.
Is Abionyx Pharma's Dividend Yield % too high?
Abionyx Pharma's current Dividend Yield % is 0.00%. Based on the distribution chart, Abionyx Pharma ranks #999999 out of 151 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Abionyx Pharma has a GF Score™ of 15/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Abionyx Pharma's Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abionyx Pharma ranks #999999 out of 151 companies for Dividend Yield %. This places Abionyx Pharma in the lower half of its industry. The industry median Dividend Yield % is 1.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.50, based on 151 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Abionyx Pharma and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abionyx Pharma's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abionyx Pharma stock overvalued right now?
Based on GuruFocus' analysis, Abionyx Pharma (FRA:609) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.80, compared to a current price of €2.17 — trading 171.3% above its estimated fair value. The current Dividend Yield % is 0.00%. Abionyx Pharma's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Abionyx Pharma (FRA:609), the current Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abionyx Pharma (FRA:609) Overvalued in 2026?
Based on GuruFocus' analysis, Abionyx Pharma stock appears to be overvalued.
The current stock price of €2.17 is trading 171.3% above its estimated GF Value™ of €0.80.
GuruFocus considers Abionyx Pharma to be Significantly Overvalued.
Key valuation signals for FRA:609:
Dividend Yield %: 0.00%
GF Value™: €0.80 vs. price of €2.17 (171.3% above fair value)
No single metric tells the full story. See the FRA:609 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.
15GF Score
Get the complete analysis for FRA:609
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:609 has been successfully added to your 
